We are live on ! Find out more
TGI

TRV GP IV Portfolio holdings

AUM $267M
1-Year Est. Return 965.83%
This Fund
S&P 500
This Quarter Est. Return
+44.29%
1 Year Est. Return
+965.83%
3 Year Est. Return
+686.22%
5 Year Est. Return
+581.56%
10 Year Est. Return
–
AUM
$271M
AUM Growth
-$40.3M
Cap. Flow
-$117M
Cap. Flow %
-43.04%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RLAY icon
Relay Therapeutics
RLAY
+$117M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.84B
$94.8M 34.93%
500,513
– –
PLRX icon
2
Pliant Therapeutics
PLRX
$64.4M
$83.9M 30.9%
2,132,867
– –
RVMD icon
3
Revolution Medicines
RVMD
$39.9B
$65.1M 24%
1,419,900
– –
FULC icon
4
Fulcrum Therapeutics
FULC
$273M
$27.6M 10.17%
2,343,154
– –
RLAY icon
5
Relay Therapeutics
RLAY
$4.1B
– –
-2,811,197
Closed -$117M

Similar funds

OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
WAM
Weinberger Asset Management Los Angeles, California $267M AUM 19.83% 1-Year Est. Return
IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
SIA
SGL Investment Advisors Missoula, Montana $266M AUM 18.29% 1-Year Est. Return
CFG
Cambridge Financial Group Columbus, Ohio $267M AUM 31.62% 1-Year Est. Return
EU
Emory University Atlanta, Georgia $267M AUM 48.26% 1-Year Est. Return
PC
Packer & Co Cottesloe, Australia $267M AUM
ALC
Alexander Labrunerie & Co Columbia, Missouri $267M AUM 21.24% 1-Year Est. Return

TRV GP IV's Q1 2021 Portfolio in Review

As of Q1 2021, TRV GP IV held 5 positions worth $271M, down 13% from $312M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP IV withdrew a net $117M in Q1 2021, closing 1 position. Its most notable exit was Relay Therapeutics, an estimated $117M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP IV fully exited Relay Therapeutics in Q1 2021, selling an estimated $117M.
  • TRV GP IV's ten largest holdings make up 100% of its $271M portfolio in Q1 2021.
  • TRV GP IV opened 0 new positions and closed 1 in Q1 2021.
  • TRV GP IV's portfolio value fell 13% quarter-over-quarter to $271M.

Based on TRV GP IV's 13F filing for Q1 2021, filed 12 May 2021.